| 刘玉辉 马楠 陈哓夏 徐龙 刘兆喆 谢晓冬.术后放化疗对淋巴结阳性食管鳞癌患者的临床意义[J].现代生物医学进展英文版,2014,14(34):6704-6706. |
| 术后放化疗对淋巴结阳性食管鳞癌患者的临床意义 |
| Clinical Significance of Postoperative Radiation and Chemotherapy inPatients with Esophageal Squamous Carcinoma Positive-Lymph Node |
| |
| DOI： |
| 中文关键词: 食管鳞癌 淋巴结阳性 术后放化疗 |
| 英文关键词: Esophageal squamous carcinoma Positive lymph node Postoperative chemoradiotherapy |
| 基金项目:2012年辽宁省科技攻关计划课题（2012225019） |
|
| Hits: 643 |
| Download times: 840 |
| 中文摘要: |
| 目的：探讨术后放化疗在治疗淋巴结阳性食管鳞癌中的毒副作用、临床预后及可能影响因素。方法：选择淋巴结阳性食管鳞
癌患者为研究对象，纳入研究患者共计64 例，术后放疗剂量为50 Gy，化疗方案为顺铂联合紫杉醇（21 d方案），观察并记录患者
不良反应情况，分析患者3 年无瘤生存情况，并进一步探讨可能影响预后的相关因素。结果：患者出现骨髓抑制（白细胞下降），其
中Ⅰ/Ⅱ度骨髓抑制39 例(61.0％)，Ⅲ/Ⅳ度骨髓抑制19 例(29.7％)；胃肠道反应Ⅰ/Ⅱ度15 例(23.4%)，Ⅲ/Ⅳ度6 例(9.4%)；无肝肾
功能异常或明显过敏反应；Ⅰ/Ⅱ度放射性食管炎和放射性气管炎分别为18 例（28.1%）和14 例(21.9%)，晚期肺损伤Ⅲ/Ⅳ度2 例
(3.1%)。64 例患者的3 年无瘤生存期为28.8 个月，无瘤生存率为46.9%。本研究未发现明显影响术后放化疗治疗淋巴结阳性食管
鳞癌患者预后的相关因素（P>0.05）。结论：淋巴结阳性食管鳞癌患者术后放化疗的不良反应主要为白细胞下降、胃肠道反应和放
射性损伤等，患者均可耐受，且3 年无瘤生存显著改善，可用于淋巴结阳性食管鳞癌患者治疗。 |
| 英文摘要: |
| Objective:To explore the side effects, clinical outcomes and possible influencing factors of postoperative
chemoradiotherapy in treatment of lymph node positive esophageal squamous cell carcinomas.Methods:As research objects, the selected
lymph node positive esophageal squamous carcinoma patients, in a total of 64 cases of patients, were given the postoperative radiotherapy
dose of 50 Gy and chemotherapy regimens for cisplatin plus paclitaxel (21 d scheme), and to observe and record adverse reactions, 3 year
disease-free survival in patients and further exploring the related factors affecting the prognosis.Results:Patients performed with bone
marrow suppression (a decrease in white blood cells), including 39 cases (61.0%) of Ⅰ/Ⅱ and 19 cases (29.7%) of Ⅲ/Ⅳ degree of bone
marrow inhibition; 15 cases (23.4%) of gastrointestinal reaction Ⅰ/Ⅱ degree, 6 cases (9.4%) of Ⅲ/Ⅳ degrees; without liver and kidney
dysfunction or significant allergic reaction; 18 cases (28.1%) and 14 cases (21.9%) respectively of Ⅰ/Ⅱ degree of radioactive esophagitis
and bronchitis, late lung injury Ⅲ /Ⅳ degree in 2 cases (3.1%). Disease-free lifetime of 3 years in 64 cases was 28.8 months, and
disease-free survival rate was 46.9%. The present study found no significant postoperative chemoradiotherapy treatment factors in relative
to the prognosis of patients with lymph node positive esophageal squamous carcinoma (P>0.05).Conclusion:Postoperative chemoradiotherapy.
in lymph node positive esophageal squamous carcinoma patients had adverse reactions tolerated mainly for white blood cells
decline, gastrointestinal reaction and radiation damage, and improved the 3-year disease-free survival of patients, can be used in treating
patients with lymph node positive esophageal squamous carcinoma. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
